News for AcelRx Pharmaceuticals, Inc. (ACRX)

High emphasis on clinical efficacy and investments in development of innovative products for pancreatic and bile duct stone management....

HOUSTON, March 6, 2024 /PRNewswire/ -- FibroBiologics, Inc. , a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and...

AcelRx Pharmaceuticals CEO purchases 10K shares, increasing total holdings to 101.8K. Recent insider trading activity shows 7 buys and 0 sales.

Operator: Welcome to the AcelRx third quarter 2023 financial results conference call.

AcelRx Pharmaceuticals, Inc. (NASDAQ:NASDAQ:ACRX) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ETCompany ParticipantsRaffi Asadorian - CFOVince...

Gainers

Goldman Sachs increased the price target for Constellation Brands, Inc. (NYSE: STZ) from $275 to $305. Goldman Sachs analyst Bonnie Herzog maintained a Buy rating. Constellation shares fell 0.8% to $254.00 in pre-market trading.

The fecal pancreatic elastase testing market sees growth opportunities in addressing pancreatic cancer, driven by new therapies and risk factors like...

On September 11, 2023, Vincent Angotti, the CEO of AcelRx Pharmaceuticals Inc (ACRX), made a significant insider purchase of 10,000 shares of the company's

AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

/PRNewswire/ -- The "Transmucosal Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key...

Divestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023 AcelRx advancing its proprietary Niyad™ nafamastat program with FDA...

Agreement with Alora Pharmaceuticals provides AcelRx with 15% royalties on commercial sales, 75% royalties on Department of Defense (DoD) sales, up to $116.5...

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) rose 115.3% to $1.40 in pre-market trading after the company announced that primary endpoint was met in study for its treatment of allergic rhinitis.

Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) shares gained 81% to $1.8503 after the company authorized a $3.5 million buyback.

Read Analysts’ New Coverage for May 29th (AACG, AAME, ABEO, ACOR, ACRX, ACU, AEMD, AEY, AEZS, AGFS) at ETF Daily News

Read Investment Analysts’ New Coverage for May 21st (AACG, AAME, ABEO, ACOR, ACRX, ACU, AEMD, AEY, AEZS, AGFS) at ETF Daily News

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.

Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the commercialization of space technologies and services.